Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05774782
Other study ID # SNSC-CFD-202204
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date March 27, 2023
Est. completion date January 2025

Study information

Verified date April 2024
Source Sinomed Neurovita Technology Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this trial is to evaluate the safety and efficacy of the cerebral flow diverter in the endovascular treatment of wide-necked cerebral aneurysms


Description:

The investigation is a prospective, multi-center, single arm clinical study. The trial is anticipated to last from March 2023 to January 2025 with 143 subjects recruited in around 10 China centers. The population for this study is subjects with wide-necked intracranial aneurysms who are suitable candidates for flow diverter implantation. Patients fulfilling all of the inclusion criteria and none of the exclusion criteria will be enrolled after offering informed consent form. The study consists of six visits including preoperative screening, operation date, 7days or at discharge, 30 days, 180 days, and 1 year. The primary endpoint is success aneurysm occlusion at 1 year post procedure.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 14
Est. completion date January 2025
Est. primary completion date January 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Age 18 years to 75 years, male or non-pregnant female. 2. Unruptured wide-necked cerebral aneurysms confirmed by preoperative imaging (Wide-necked is defined as width = 4 mm or a dome-to-neck ratio < 2). 3. Parent vessel with a diameter range of 1.75-6.0 mm. 4. Those who voluntarily participate in the study and sign informed consent form. Exclusion Criteria: 1. Subject with target aneurysms are blood blister-like aneurysms, pseudoaneurysms, arteriovenous malformation, moyamoya disease-related aneurysm, or multiple aneurysms that cannot be treated with a single stent. 2. Severe arteriosclerosis or tortuosity of intracranial artery, and the device is difficult to reach the target vessel. 3. Subject with target aneurysm previously treated with craniotomy or other endovascular interventional therapy. 4. Known sensitivity to antiplatelet medications, anticoagulant medications, radiographic contrast agents, anesthetic, nickel, platinum-tungsten alloy, platinum-iridium alloy, and poly-N-[Tris(hydroxymethyl)methyl] acrylamide (poly-NTMA). 5. Severe respiratory system, liver and kidney diseases (such as creatinine = 3.0 mg/dL (except dialysis)) or blood coagulation disorders before operation. 6. Platelet count is less than 100×109/L, international normalized ratio (INR) is more than 1.5. 7. Hospitalized surgical treatment within the previous 30 days or planned within the next 180 days after operation. 8. Severe neurological deficit that renders the patient incapable of living independently (modified Rankin score =3). 9. The survival expectation is less than 1 year. 10. All subjects who are participating in other drug/medical device clinical trials and have not completed the programme requirements 11. Inapplicable for this study at the investigators' viewpoints.

Study Design


Intervention

Device:
Cerebral flow diverter
The surface-modified flow diverter is an intracranial implant designed to be placed in a parent artery so as to divert blood flow away from an aneurysm.

Locations

Country Name City State
China Xuanwu Hospital Capital Medical University Beijing

Sponsors (2)

Lead Sponsor Collaborator
Sinomed Neurovita Technology Inc. Xuanwu Hospital, Beijing

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Success aneurysm occlusion at 1 year post procedure The Raymond-Roy occlusion classification (RROC) is an angiographic classification scheme for grading the occlusion of flow diverter treated cerebral aneurysms (class I: complete obliteration, class II: residual neck, class III: residual aneurysm). Higher class represent a worse outcome. The percentage of Success aneurysm occlusion in which class 1 or 2 is achieved on the Raymond Scale at the 1 year follow-up angiographic assessments will be evaluated. 1 year post procedure
Secondary Immediate procedural success rate Intraoperative cerebrovascular imaging is performed to determine whether the investigational device positions exactly and covers the aneurysm neck effectively. Intra-procedure
Secondary Complete aneurysm occlusion rate at 180 days and 1 year post procedure Complete occlusion was defined as complete obliteration of the aneurysm sac, including the neck (Raymond I). 180 days, 1 year post procedure
Secondary Success aneurysm occlusion at 180 days post procedure The Raymond-Roy occlusion classification (RROC) is an angiographic classification scheme for grading the occlusion of flow diverter treated cerebral aneurysms (class I: complete obliteration, class II: residual neck, class III: residual aneurysm). Higher class represent a worse outcome. The percentage of Success aneurysm occlusion in which class 1 or 2 is achieved on the Raymond Scale at the 180 days follow-up angiographic assessments will be evaluated. 180 days post procedure
Secondary Complete aneurysm occlusion without significant parent artery stenosis (=50%) or retreatment at 180 days and 1 year post procedure Proportion of subjects with complete occlusion of the target aneurysm, =50% stenosis of the parent artery at the target cerebral aneurysms at 1 year as assessed by angiography, and in whom an unplanned alternative treatment of the target cerebral aneurysms had not been performed within 1 year. 180 days, 1 year post procedure
Secondary All-cause mortality at 30 days, 180 days and 1 year post procedure Deaths due to any cause are calculated. 30 days, 180 days and 1 year post procedure
Secondary Any stroke at 30 days, 180 days and 1 year post procedure Incidence of any stroke including ischemic and hemorrhagic stroke. 30 days, 180 days and 1 year post procedure
Secondary Major stroke in the territory supplied by the treated artery or neurological death at 180 days and 1 year post procedure National Institute of Health Stroke Scale (NIHSS) was used to assess patients after stroke in an 11-item scale with potential scores ranging from 0 to 42. Higher values represent a worse outcome. A major stroke is defined as a new neurological event which is ipsilateral and in the vascular distribution territory of the stenting procedure and that results in an increase of = 4 on the NIHSS as compared to baseline. 180 days and 1 year post procedure
Secondary Target aneurysmal hemorrhage at 180 days and 1 year post procedure Percentage (%) of participants who experienced a Target aneurysmal hemorrhage. 180 days and 1 year post procedure
Secondary Ischemic cerebrovascular events caused by thromboembolism at 180 days and 1 year post procedure Percentage (%) of participants who experienced ischemic cerebrovascular events caused by thromboembolism. 180 days and 1 year post procedure
Secondary Incidence of operation or device-related adverse events/serious adverse events during hospitalization, 30 days, 180 days and 1 year post procedure Percentage (%) of participants who experienced adverse events/serious adverse events. hospitalization, 30 days, 180 days and 1 year post procedure
Secondary Rate of Device defect Device defects refer to the unreasonable risks that may endanger human health and life safety during the normal use of medical devices in the course of clinical trials, such as label errors, quality problems, failures, etc. within 1 year of whole trial
See also
  Status Clinical Trial Phase
Recruiting NCT04583163 - Variability in Transcranial Doppler Technique in Neuro-Critical Care Patients
Recruiting NCT03306823 - Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation 1 N/A
Recruiting NCT03306836 - Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation 2 N/A
Recruiting NCT02345395 - Safety Study of Minimally Invasive Approaches to Unruptured Anterior Circulation Aneurysms N/A
Completed NCT00962546 - Computed Tomographic (CT) Perfusion and CT Angiography as Screening Tools for Vasospasm Following Subarachnoid Hemorrhage N/A
Recruiting NCT04141020 - Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms Phase 2
Recruiting NCT01460563 - Valproic Acid, Magnesium Sulphate, Rocuronium Requirement, Postoperative Analgesia N/A
Completed NCT02507999 - Goal-directed Therapy in Endovascular Coiling of Cerebral Aneurysm Patients N/A
Recruiting NCT02162654 - Remote Ischemic Preconditioning for Intracranial Aneurysm Treatment N/A
Completed NCT01943591 - DELTA Trial: Does Embolization With Larger Coils Lead to Better Treatment of Aneurysms Trial N/A
Recruiting NCT03815149 - Safety and Clinical Effectiveness of Pipeline™ Shield Devices for Intracranial Aneurysms
Completed NCT03152201 - New Findings About Somatosensory Evoked Potentials (SEP) During Surgery for Cerebral Aneurysms
Recruiting NCT02444832 - Multicenter Retrospective Registry of Anterior Communicating Artery Aneurysms With Endovascular Therapy N/A
Withdrawn NCT01878136 - Effect of Intraventricular tPA Following Aneurysmal Subarachnoid Hemorrhage Phase 1/Phase 2
Withdrawn NCT02011321 - Clevidipine for Vasospasm After Subarachnoid Hemorrhage (SAH) Phase 2
Completed NCT02455440 - Esmolol Infusion in Patients Undergoing Craniotomy Phase 3
Completed NCT00614887 - Hypothalamo-, Pituitary-, Adrenal Axis Dysfunction in Subarachnoid Hemorrhage
Terminated NCT02281721 - Surpass Flow Diverter for Intracranial Aneurysms: SURMOUNT Registry Data Collection
Completed NCT04963933 - A Medical Device to Treat Brain Aneurysms N/A
Completed NCT02700607 - Impact of Intravascular Fluid Resuscitation and Whole Blood Viscosity N/A